The number of treatment options for metastatic hormone-sensitive prostate cancer has increased substantially in recent years.The classic treatment approach for these patients—androgen-deprivation therapy alone—is now considered suboptimal.Several randomized phase III clinical trials have demonstrated ...
1. Research advances in the role of bisphosphonates in preventing BMD loss in hormone-sensitive prostate cancer patients undergoing androgen deprivation therapy; 双磷酸盐对接受去势治疗的激素敏感型前列腺癌患者防治骨质丢失的研究进展2) Androgen-dependent prostate cancer 激素敏感性前列腺癌3) androgen ...
Androgen-receptor signaling inhibitors (ARSIs) become the new standard of care for metastatic hormone-sensitive prostate cancer (mHSPC). It is unknown whether time to castration resistance (TTCR), when using the first-line ARSIs, offers predictive value in mHSPC. We sought to assess the clinical ...
Results of the STAMPEDE and LATITUDE trials, which investigated the addition of abiraterone and prednisone to androgen-deprivation therapy in advanced prostate cancer, have renewed interest in 'complete androgen blockade', a concept originally described by Fernand Labrie in the 1980s. However, whether ...
Amir Goldkorn, MD, discusses circulating tumor cell count, a beneficial biomarker in patients with metastatic castration-sensitive prostate cancer.
Clinical Trials Test Bisphosphonates in Hormone-Sensitive Prostate Cancer.Reports on clinical trials to test the potential of biphosphonates in preventing bone loss and bone-related complications in patients with hormone-sensitive metastatic disease. Reduction of the risk of cancer-related skeletal-related...
Men with metastatic hormone-sensitive prostate cancer treated with darolutamide plus ADT in the phase 3 ARANOTE trial had improved radiologic progression-free survival compared with placebo.
Introduction In patients with metastatic hormone-sensitive prostate cancer (mHSPC) undergoing intensified androgen deprivation therapy (ADT), not achieving an optimal PSA response, defined as PSA nadir >0.2?ng/ml (PSAsubOR) has been asso... G Georges,S Nicolas,Vinay Mathew,ThomasBeverly,ChigariraN...
Androgen deprivation therapy remains the backbone therapy for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). In recent years, several treatments, including docetaxel, abiraterone + prednisone, enzalutamide, and apalutamide, have each been shown to demonstrate survival benefit when ...
Fred Saad, CQ, MD, FRCS, FCAHS, discusses how darolutamide offers potential advantages over other androgen receptor–targeted therapies for metastatic prostate cancer, including its unique molecular structure, favorable safety profile, and efficacy in specific clinical scenarios. ...